Abstract

Aluminum adjuvants have been instrumental in enhancing the efficacy of vaccines by augmenting the immune response. However, concerns have been raised regarding their biopersistence and potential migration to the brain, leading to neurological complications. This article provides a comprehensive overview of the journey of aluminum adjuvants following vaccination, focusing on their biopersistence and potential translocation to the central nervous system. We examine the mechanisms underlying aluminum adjuvant uptake, distribution, and retention in the body, as well as the evidence supporting their passage across the blood-brain barrier. Additionally, we explore the implications of aluminum adjuvant neurotoxicity and the controversies surrounding their safety profile. Understanding the dynamics of aluminum adjuvants in vaccine-induced immunity is essential for informed decision-making and the development of safer vaccination strategies